Items where authors include "Duncan, CJA"

Article

Al-Hakim, A, Poulter, JA orcid.org/0000-0003-2048-5693, Mahmoud, D et al. (9 more authors) (2022) Allogeneic hematopoietic stem cell transplantation for VEXAS syndrome - UK experience. British Journal of Haematology, 199 (5). pp. 777-781. ISSN 0007-1048

Ferrada, MA, Savic, S orcid.org/0000-0001-7910-0554, Ospina Cardona, D et al. (29 more authors) (2022) Translation of cytoplasmic UBA1 contributes to VEXAS syndrome pathogenesis. Blood, 140 (13). pp. 1496-1506. ISSN 0006-4971

Shields, AM, Tadros, S, Al-Hakim, A et al. (20 more authors) (2022) Impact of vaccination on hospitalization and mortality from COVID-19 in patients with primary and secondary immunodeficiency: The United Kingdom experience. Frontiers in Immunology, 13. 984376. ISSN 1664-3224

Tomic, A, Skelly, DT, Ogbe, A et al. (105 more authors) (2022) Divergent trajectories of antiviral memory after SARS-CoV-2 infection. Nature Communications, 13 (1). 1251. ISSN 2041-1723

Angyal, A, Longet, S, Moore, SC et al. (176 more authors) (2022) T-cell and antibody responses to first BNT162b2 vaccine dose in previously infected and SARS-CoV-2-naive UK health-care workers: a multicentre prospective cohort study. The Lancet Microbe, 3 (1). e21-e31. ISSN 2666-5247

Swanson, PA, Padilla, M, Hoyland, W et al. (67 more authors) (2021) AZD1222/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike protein-specific Th1 response with a diverse TCR repertoire. Science Translational Medicine, 13 (620). eabj7211. ISSN 1946-6234

Payne, RP, Longet, S, Austin, JA et al. (132 more authors) (2021) Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine. Cell, 184 (23). 5699-5714.e11. ISSN 0092-8674

Flaxman, A, Marchevsky, NG, Jenkin, D et al. (184 more authors) (2021) Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002). The Lancet, 398 (10304). pp. 981-990. ISSN 0140-6736

Skelly, DT, Harding, AC, Gilbert-Jaramillo, J et al. (92 more authors) (2021) Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern. Nature Communications, 12 (1). 5061.

Swanson, PA, Padilla, M, Hoyland, W et al. (63 more authors) (2021) T-cell mediated immunity after AZD1222 vaccination : a polyfunctional spike-specific Th1 response with a diverse TCR repertoire. medRxiv. (Submitted)

Emary, KRW, Golubchik, T, Aley, PK et al. (64 more authors) (2021) Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7) : an exploratory analysis of a randomised controlled trial. The Lancet, 397 (10282). pp. 1351-1362. ISSN 0140-6736

Voysey, M, Costa Clemens, SA, Madhi, SA et al. (763 more authors) (2021) Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. The Lancet, 397 (10277). pp. 881-891. ISSN 0140-6736

Voysey, M, Clemens, SAC, Madhi, SA et al. (80 more authors) (2020) Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. The Lancet, 397 (10269). pp. 99-111. ISSN 0140-6736